Literature DB >> 26990230

A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus.

Valerio Mammoli1, Alessandro Bonifazi1,2, Diego Dal Ben1, Mario Giannella1, Gianfabio Giorgioni1, Alessandro Piergentili1, Maria Pigini1, Wilma Quaglia1, Ajiroghene Thomas1, Amy H Newman2, Sergi Ferré3, Marta Sanchez-Soto3, Thomas M Keck2,4, Fabio Del Bello5.   

Abstract

Over the years, the 2-substituted imidazoline nucleus has been demonstrated to be a bioversatile structural motif. In this study, novel imidazoline derivatives bearing a 3- and/or 4-hydroxy- or methoxy-substituted phenyl ring, linked by an ethylene bridge to position 2 of an N-benzyl- or N-phenethyl-substituted imidazoline nucleus, were prepared and studied against D2 -like receptor subtypes. Binding studies highlighted that a set of N-phenethylimidazoline compounds are selective for D4 over D2 and D3 receptors. In functional assays, the 3-methoxy-substituted derivative, endowed with the highest D4 affinity value, and its 3-hydroxy analogue behaved as partial agonists with low intrinsic efficacy and as competitive D4 antagonists when tested in the presence of the D2 -like receptor agonist quinpirole. Molecular docking analysis, performed using a homology model of the human D4 receptor developed using the X-ray crystal structure of the antagonist-bound human D3 receptor as a template, was in accordance with the binding results and provided useful information for the design of novel imidazoline D4 receptor ligands based on this new scaffold.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  D4 receptor antagonists; dopamine; drug design; imidazolines; privileged structures

Mesh:

Substances:

Year:  2016        PMID: 26990230      PMCID: PMC4993638          DOI: 10.1002/cmdc.201600022

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  50 in total

1.  Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes.

Authors:  Frank Boeckler; Harald Lanig; Peter Gmeiner
Journal:  J Med Chem       Date:  2005-02-10       Impact factor: 7.446

2.  Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons.

Authors:  E V Gurevich; J N Joyce
Journal:  Neuropsychopharmacology       Date:  1999-01       Impact factor: 7.853

3.  Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine?

Authors:  Claudia Cardinaletti; Laura Mattioli; Francesca Ghelfi; Fabio Del Bello; Mario Giannella; Ariana Bruzzone; Hervé Paris; Marina Perfumi; Alessandro Piergentili; Wilma Quaglia; Maria Pigini
Journal:  J Med Chem       Date:  2009-11-26       Impact factor: 7.446

Review 4.  Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates.

Authors:  Stefan Löber; Harald Hübner; Nuska Tschammer; Peter Gmeiner
Journal:  Trends Pharmacol Sci       Date:  2011-01-12       Impact factor: 14.819

5.  Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.

Authors:  Meena V Patel; Teodozyj Kolasa; Kathleen Mortell; Mark A Matulenko; Ahmed A Hakeem; Jeffrey J Rohde; Sherry L Nelson; Marlon D Cowart; Masaki Nakane; Loan N Miller; Marie E Uchic; Marc A Terranova; Odile F El-Kouhen; Diana L Donnelly-Roberts; Marian T Namovic; Peter R Hollingsworth; Renjie Chang; Brenda R Martino; Jill M Wetter; Kennan C Marsh; Ruth Martin; John F Darbyshire; Gary Gintant; Gin C Hsieh; Robert B Moreland; James P Sullivan; Jorge D Brioni; Andrew O Stewart
Journal:  J Med Chem       Date:  2006-12-14       Impact factor: 7.446

Review 6.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

7.  Discriminative-stimulus effects of methamphetamine and morphine in rats are attenuated by cAMP-related compounds.

Authors:  Yijin Yan; Atsumi Nitta; Tomoko Mizuno; Akira Nakajima; Kiyofumi Yamada; Toshitaka Nabeshima
Journal:  Behav Brain Res       Date:  2006-07-20       Impact factor: 3.332

8.  PD168077, a D(4) receptor agonist, reverses object recognition deficits in rats: potential role for D(4) receptor mechanisms in improving cognitive dysfunction in schizophrenia.

Authors:  Pooja Sood; Nagi F Idris; Susan Cole; Ben Grayson; Joanna C Neill; Andrew M J Young
Journal:  J Psychopharmacol       Date:  2010-11-18       Impact factor: 4.153

Review 9.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Authors:  P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-02       Impact factor: 4.388

10.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.